NICE approves Merck's Simponi; Alimera resubmits Iluvien NDA;

 @FierceBiotech: Pharma CEOs talk tough about unproductive R&D spending. Item | Follow @FierceBiotech

 @JohnCFierce: Here's an interesting idea: Take GSK, AZ and the University of Manchester, get each to invest £5 million and create an R&D center for inflammatory diseases.  Follow @JohnCFierce

> NICE has changed its mind on Merck's rheumatoid arthritis treatment, Simponi, after the company agreed to drop the price of its 100-mg treatment to equal the 50-mg cost. The TNF inhibitor is pricier than its counterparts, including Pfizer's Enbrel, Abbott's Humira and Janssen's Remicade. News

> Atlanta-based Alimera Sciences has resubmitted its NDA for Iluvien, a diabetic macular edema drug. The application addresses the FDA's safety concerns from a complete response letter received in December 2010. The company expects the FDA will review the Class 2 resubmission within the next six months. Alimera release 

> Biodel hopes to raise $30 million through stock offerings. The antidiabetic company will sell 12.2 million shares of common stock, 1.7 million shares of Series A convertible preferred stock and warrants to purchase another 9 million common stock shares. Article

> Ziopharm has submitted an IND application with the FDA for Ad-RTS-IL-12, a DNA-based melanoma therapy. The company has already completed preclinical trials and a Phase Ib trial on the drug. Ziopharm release

Pharma News

@FiercePharma: Ranbaxy scrambles to deliver on Nexium supply deal. News | Follow @FiercePharma

> Pfizer sets aside $772M for settling Prempro case. Article

> WSJ: Feds want $1B settlement in J&J Risperdal probe. Report

> Google near $500M settlement in pharmacy probe. Story

> Takeda says no deal for Nycomed. Sources say, 'not yet.' Item

And Finally... A McGill University survey found that one in five physicians and psychiatrists have prescribed a placebo to patients, and 35 percent of psychiatrists admitted to prescribing subtherapeutic doses of medication. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.